SLC5A2 and chronic kidney disease: The DAPA-CKD clinical trial [33] has demonstrated robust data on the role of sodium-glucose cotransporter-2 (SGLT2) inhibitors in slowing CKD progression in patients with chronic kidney disease (GFR 25–75 mL/min/1.73 m2), regardless of the presence or absence of diabetes, when comparing dapaglifozin with placebo (hazard ratio (HR), 0.61; 95% confidence interval (CI), 0.51 to 0.72; p < 0.001).